Global Cytotoxic Drugs and HPAPI Manufacturing Markets 2022-2035: Increasing Demand has Led to a Rise in the Number of HPAPIs in the Overall Pharmaceutical Development Pipeline

19 Dec 2022
www.prnewswire.com
Acquisition
DUBLIN, Dec. 19, 2022 /PRNewswire/ -- The "Cytotoxic Drugs and HPAPI Manufacturing Market by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly Potent Finished Dosage Form, and Key Geographies, Europe, Asia-Pacific and Rest of the World: Industry Trends and Global Forecasts, 2022-2035" report has been added to
ResearchAndMarkets.com's offering.
"Cytotoxic Drugs and HPAPI Manufacturing Market 2022-2035" report features an extensive study of the current market landscape and future potential of the HPAPI and cytotoxic drug manufacturing market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
Aided by the ongoing advancements in clinical pharmacology and oncology research, as well as the rising demand for targeted therapies, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have emerged as one of the key areas of interest for researchers and drug developers worldwide.
One of the key objectives of the report was to evaluate the current opportunity and the future growth potential of the HPAPI and cytotoxic drug manufacturing market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features a likely distribution of the current and forecasted opportunity across important parameters.
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
Frequently Asked Questions
What are the current opportunities within the HPAPI and cytotoxic drug market?
The cytotoxic drugs and HPAPI manufacturing market is presently considered as one of the most powerful and dynamic sectors of the pharmaceutical industry.
At present, more than 40% of the total number of drugs are highly potent in nature. Further, around 60% of the HPAPIs are being developed against oncological indications. Considering the upsurge in demand for novel anti-cancer therapeutics, including antibody-drug conjugates (ADCs), high potency compounds have generated significant interest among several researchers and industry stakeholders.
What is the need for contract manufacturing organizations (CMOs) in the HPAPI and cytotoxic drug domain?
The manufacturing of highly potent APIs and cytotoxic drugs requires an adequate working environment (to prevent cross contamination within multi-product assets), stringent manufacturing protocols (to comply with the established regulatory standards) and a trained workforce (to satisfactorily handle highly potent materials).
In addition, it requires an expensive infrastructure, which is often complex to engineer, install and maintain. As a result, various companies rely on third party service providers to leverage their technologies for manufacturing highly potent and cytotoxic compounds and achieve greater operational flexibility. The inherent expertise of CMOs is believed to be capable of enabling reduction in the time-to-market a product and offer significant cost-benefits.
What is the current market landscape and recent trends in the HPAPI and cytotoxic drug contract manufacturing domain?
Presently, close to 145 companies have the required capabilities to offer HPAPI and cytotoxic drug manufacturing services across different scales of operation.
In addition, several contract service providers are entering into strategic alliances in order to consolidate their presence in this field and enhance their existing capabilities to meet the growing demand for high potency molecules. It is worth mentioning that close to 50% of the expansion activities carried out in this market have been focused on improving the existing manufacturing facilities for highly potent molecules, through the addition of new structures and equipment.
What are the key challenges faced by HPAPI and cytotoxic drug CMOs?
The primary challenge faced during the manufacturing of highly potent APIs and cytotoxic drugs is related to limiting / altogether preventing cross-contamination of the highly potent molecule with other molecules being produced at the same site.
Further, the lack of information related to safe exposure levels and toxicity of new chemical entities can risk the lives of workers and harm the environment. As a result, comprehensive management systems are required for safe handling and containment of highly potent molecules.
In addition, proper cleaning techniques and waste treatment systems are extremely essential while producing such compounds.
What are the key value drivers in the HPAPIs and cytotoxic drugs contract manufacturing market?
The increasing demand for cytotoxic drugs has led to a rise in the number of HPAPIs in the overall pharmaceutical development pipeline. In order to cater to the growing demand for the production of such drug candidates, there is a requirement for safe manufacturing and containment technologies.
Even though some pharmaceutical companies have made considerable investments to establish in-house capabilities, the capital-intensive nature and specialized containment requirements make the role of contract manufacturers crucial, specifically for small and mid-sized players.
How is the revenue generation potential associated with cytotoxic drugs and HPAPI manufacturing market likely to evolve in the coming years?
The cytotoxic drugs and HPAPI manufacturing market is projected to grow at a CAGR of approximately 12% in the coming years. Currently, in terms of type of molecule, the market is likely to be driven by highly potent small molecules. However, this trend is expected to change in the foreseen future, as the demand for highly potent biologics, such as cell and gene therapies, increases further.
In addition, in terms of scale of operation, majority share of the contract service revenues is expected to be generated by commercial scale manufacturing operations. Specifically, in terms of geography, the cytotoxic drugs and HPAPI manufacturing market in Asia-Pacific is likely to grow at a relatively faster pace (~13%), in the long term.
The report features detailed transcripts of interviews held with the following individuals:
Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)
Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent)
Roberto Margarita (Business Development Director, CordenPharma)
Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora research)
Mark Wright (Ex-Site Head, Grangemouth, Piramal Healthcare)
Allison Vavala (Ex-Senior Manager, Business Development, Helsinn)
Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma)
Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)
COMPANY COMPETITIVENESS ANALYSIS
HPAPI Contract Manufacturers: Company Competitiveness Analysis
Highly Potent FDF Contract Manufacturers: Company Competitiveness Analysis
HPAPI and Highly Potent FDF Contract Manufacturers: Company Competitiveness Analysis
COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN NORTH AMERICA
COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN EUROPE
Abzena
Aenova
CARBOGEN AMCIS
Lonza
COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN ASIA-PACIFIC AND REST OF THE WORLD
Scinopharm
Teva API
LIST OF COMPANIES AND ORGANIZATIONS
Abzena
Aenova
ALB Technology
Alkermes
AMPAC Fine Chemicals (A SK pharmteco company)
Angelini Fine Chemicals (A subsidiary of Angelini Pharma)
Aptuit (An Evotec company)
Ardena
Arevipharma (Acquired by Yonsung Group)
Aspen API
Astorg
Bryllan
Capsugel (A Lonza company)
ChemPartner
CordenPharma
Curia
Custom Pharmaceutical Services (A part of Dr. Reddy's Laboratories)
Cytopharma
Daiichi Sankyo
Dipharma
DOTTIKON EXCLUSIVE SYNTHESIS
Esteve
Excella (Acquired by Fareva)
Fabbrica Italiana Sintetici
Fareva
Farmhispania
Fermion (A subsidiary of Orion)
Flamma
Formex (A subsidiary of Biotech Investment Group (BIG))
Fresenius Kabi
GENTEC PHARMACEUTICAL GROUP
GP Pharm
Gustave Roussy
ICROM
Idifarma (Acquired by Ardena)
IDT Australia
Indena
Kohlberg
LakePharma
Lonza
Mac-Chem (A NMS Group Company)
Magle Chemoswed
McSAF
Minafin
Minakem (A subsidiary of Minafin)
Mubadala
MuseChem
Normon
OEP Pharma
Parabolic Drugs
Pensatech Pharma
Pfanstiehl
PILA PHARMA
Procos (A subsidiary of CBC)
Recipharm
Richman Chemical
Sartorius
ScinoPharm Taiwan
Seagen
SEQENS (Acquired by SK Capital Partners)
Siegfried
Sofpromed
Somatek
Synbias Pharma
Teva API
Tubulis
University of Goettingen
Vectura
Veranova
VUAB Pharma (A SAFICHEM company)
Wavelength Pharmaceuticals (A subsidiary of SEQENS)
For more information about this report visit https://www.researchandmarkets.com/r/szmg8r
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.